TickerTalks
Browse all tickers →
TickerTalks›$MTC
MTMTC

MMTec, Inc.

$MTC·$77M·Software - Application·Technology
$3.29+12.7%YTD-14.6%1Y+210.0%
Mentions · last 7 days
2026-07-21: 1 posts2026-07-22: 2 posts2026-07-23: 1 posts2026-07-24: 1 posts2026-07-25: 1 posts2026-07-26: 0 posts2026-07-27: 1 posts7+17%
Price updated 5m ago·X counts updated 23h ago
MTMTC
$MTCMMTec, Inc.
$3.29+12.67%7 posts+17%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $MTC, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeCooling offAI verdict · as of 2026-07-28

Catching its breath after a run — could pick back up or fade from here.

China-based securities-trading platform up 210% over 12 months on effectively zero revenue — this is a symbol-recognition trade, not a business.

MMTec provides securities-trading platforms serving financial institutions in China — a $77M micro-cap with essentially zero recent revenue that has traded up 210% over 12 months on symbol-recognition flows tied to the AI-cashtag rally.

  • Q4 revenue of zero and Q2 revenue of -$20M (an accounting reversal, not a business) — the P&L shows no consistent operating model.
  • Stock down 15% year-to-date but up 210% over 12 months, at 30% of the 52-week range — the tape is fading the earlier run, which is the direction to lean.
  • Negative -0.15 beta plus tiny 0.45x volume — the illiquidity means any concentrated selling can compound the fade quickly.

No confirmed next earnings date — any operational reset that produces meaningful revenue is the only real re-rate lever, while continued fade of the recognition-driven rally is the more likely path. Risk: symbol-recognition-driven trades in tiny-float US-listed Chinese names typically retrace to pre-rally levels once the specific narrative fades.

Differs from X sentimentNo X chatter in the bundle for MTC to compare against the hot-momentum-cooling read — flagging as no-crowd-read.

What to watch: Any earnings release with meaningful revenue detail — plus any strategic-partnership or capital-raise announcement that would change the operational base.

Read the AI verdict + X sentiment for $MTC

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Chinese fintech developing securities trading and settlement platforms for financial institutions globally.

Industry overviewAI analysisGenerated by AI from underlying data

Where Software - Application sits in its cycle right now — and what that implies for $MTC.

Software - Application · Technology

No material change from last week — platforms where agents expand contract value (ServiceNow, Snowflake) are re-rated upward, while tools where agents substitute human users (Adobe Creative..

Top industry ETF

$IGViShares Expanded Tech-Software Sector ETF
-14.6%YTD
-19.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-272%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
239%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-4.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
-3.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
21.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
104%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 8, 2026$-0.24——
Q2 2025Jul 9, 2025$-1.84——
Q2 2024Jul 30, 2024$-1.14——
Q3 2023Oct 20, 2023$-0.46——

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$0-100.0%——$-0.24$-2.0M
Q2 FY25$-20.5M-817.1%101%230%$-1.84$-1.7M
Q4 FY24$1.9M+410.8%79.3%-3505%$-2.50$2.6M
Q2 FY24$0-100.0%——$-1.14$-1.9M

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.30%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-18.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-22.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 25.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-0.155-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsMar 313
3New insider — initial holdingsMar 313
3New insider — initial holdingsMar 313
3New insider — initial holdingsMar 313
3New insider — initial holdingsMar 313
+ 2 other (1 20-F · 1 6-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platformbusinesswire.com·35d agoLilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopausegurufocus.com·51d agoLilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and igurufocus.com·52d ago

More in Software - Application

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NOW$ZETA$MSTR$U$UBER$BULL$CRM$ADBE
Voices on X · last 7 days

No standout posts about $MTC on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport